Some patients carry genetic variants that reduce how effectively their GLP-1 receptors respond to the medication, leading to what researchers call 'primary non-response.' Others develop tolerance as their bodies adapt to the drug over weeks or months, a phenomenon called 'tachyphylaxis.' Lifestyle factors also play a measurable role
The trial demonstrated positive results in terms of both lean mass retention and weight loss, but researchers recommend continued clinical development and refinement of the drug combination to better understand the common adverse events observed in the bimagrumab groups, such as mild-to-moderate acne and muscle spasms
If you are experiencing intolerable side effects, consult with your healthcare provider
This delivery method ensures 100% bioavailability, bypassing the digestive system for maximum absorption
Antioxid (Basel) 13
[PMC free article] [PubMed] [Google Scholar] Wood 2008 Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al